Table D1Characteristics of cross-sectional studies evaluating the test performance of reticulocyte hemoglobin content (CHr) for assessing iron status as defined by classical laboratory markers

Study, Year
[Pubmed ID]
Country
Sampling PopulationNenrolled/NanalyzedDemographicsKidney Function IndicesAnemia and Iron Status IndicesBackground Treatment
Adult HD CKD
Bhandari, 19976
[9398126]
UK
HD CKD22/22Male (%): 73
Age (yr): 62
Race (%): NR
NRHb (g/dL): NR
Hct (%): NR
ferritin (ng/mL): 33.4 μg/L [range, 4 to 56 μg/L]
TSAT (%): 25.1
ESA dose: 6055 IU/wk

Iron washout: No washout
Bhandari, 19987
[9589378]
UK
HD CKD72/72Male (%): 72
Age (yr): 62
Race (%): NR
NRHb (g/dL): NR
Hct (%): NR
ferritin (ng/mL): NR (≤100 in 64%)
TSAT (%): NR (≤20 in 51%)
ESA dose: 2000 IU/wk

Iron washout: No washout
Cullen, 19999
[10193816]
Germany
HD CKD36/25Male (%): 47
Age (yr): 64
Race (%): 100%
Caucasian
NRHb (g/dL): 9.4
Hct (%): NR
ferritin (ng/mL): 427.3
TSAT (%): 19.5
ESA dose: NR (All patients received ESA treatment intermittently before the start of the study)

Iron washout: No washout
Kaneko, 200315
[12631092]
Japan
HD CKD197/197Male (%): 61
Age (yr): 59
Race (%): NR
NRHb (g/dL): NR
Hct (%): 31.3
ferritin (ng/mL): 247.4
TSAT (%): 25.8
ESA dose: 4116 IU/wk

Iron washout: No washout
Kim, 200816
[18190467]
South Korea
HD CKD140/140Male (%): 49
Age (yr): 56
Race (%):NR
NRHb (g/dL): 10
Hct (%): 32.6
ferritin (ng/mL): 224.5
TSAT (%): 27.6
ESA dose: NR (all patients received rHuEpo alpha intravenously)

Iron washout: 3 wks
Miwa, 201018
[19624802]
Japan
HD CKD217/752 samples (multiple samples from single subject)Male (%): 59
Age (yr): 58
Race (%):NR
NRHb (g/dL): 10.3
Hct (%): 33
ferritin (ng/mL): 74.4
TSAT (%): 20.8
ESA dose: 5069 IU/wk

Iron washout: No washout and no change allowed in dose
Tsuchiya, 200319
[12608554]
Japan
HD CKD149/149Male (%): 38
Age (yr): 55
Race (%): NR
NRHb (g/dL): 10.2
Hct (%): 32.4
ferritin (ng/mL): 98.1
TSAT (%): 23
ESA dose: 93.1 IU/kg/wk (n=120, patients received EPO treatment)

Iron washout: No washout and no change allowed in dose
Adult PD CKD
Eguchi, 201011
[20415234]
Japan
PD CKD19/85 samples (multiple samples from single subject)Male (%): 26
Age (yr): 48.6
Race (%):NR
BUN (mg/dL): 56
Creatinine (mg/dL): 11.6
Hb (g/dL): 9.8
Hct (%): 29.9
ferritin (ng/mL): 197.8
TSAT (%): 32.6
ESA dose: 17,833 IU/month (Epoetin-beta); 88.2 μg/month (darbepoetin-alpha)

Iron washout: NR

BUN=blood urea nitrogen; CHr=content of hemoglobin in reticulocytes; CKD=chronic kidney disease; Dx=diagnosis; ESA=erythropoiesis stimulating agents; ESRD=end stage renal disease; Hb=hemoglobin; HD=hemodialysis; Hct=hematocrit; IV=intravenous; IU=international units; NR=not reported; PD=peritoneal dialysis; TSAT=transferrin saturation; wk=week; yr=year

From: Appendix D, Test Performance of Newer Markers for Assessing Iron Status as Defined by Classical Laboratory Markers

Cover of Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease
Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease [Internet].
Comparative Effectiveness Reviews, No. 83.
Chung M, Moorthy D, Hadar N, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.